The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson' s disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson' s disease.